Which KRAS G12C Inhibitors are Currently Approved?
Sotorasib (Lumakras) is the first KRAS G12C inhibitor approved by the FDA for the treatment of KRAS G12C-mutated NSCLC. Other inhibitors, such as adagrasib, are currently under clinical investigation and showing promising results in clinical trials.
